Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
about
Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cellsDual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissueLatent reservoirs of HIV: obstacles to the eradication of virusA stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected childrenThe epidemiological impact of antiretroviral use predicted by mathematical models: a review.Different patterns of HIV-1 DNA after therapy discontinuation.Manipulation of the host protein acetylation network by human immunodeficiency virus type 1Quantification of viral infection dynamics in animal experimentsVery early combination antiretroviral therapy in infants: prospects for cureThe immunological synapse: the gateway to the HIV reservoirSlow turnover of HIV-1 receptors on quiescent CD4+ T cells causes prolonged surface retention of gp120 immune complexes in vivoTargeting the Brain Reservoirs: Toward an HIV CureDepletion of latent HIV-1 infection in vivo: a proof-of-concept studyMacrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humansViral and latent reservoir persistence in HIV-1-infected patients on therapyART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremiaOptimal timing and duration of induction therapy for HIV-1 infectionTherapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAARTHIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirsPredicting the outcomes of treatment to eradicate the latent reservoir for HIV-1HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationEradication therapies for HIV Infection: time to begin again.HIV pathogenesis: dynamics and genetics of viral populations and infected cells.Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells.Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection.Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAARTLow-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcomeIn vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapyHIV persistence: chemokines and their signalling pathways.Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiencyIdentification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers.
P2860
Q24534863-45E9C350-803C-4165-BC93-A445EBF3BF49Q24548940-859C0C5B-1805-4239-B095-70D3D9C301A6Q24562082-CC808C25-876E-48FB-80CB-A2912F2DE945Q24615570-DFCAC4E0-6AD5-4D29-BA94-C68248FD8A6DQ24620746-932653E0-5534-4226-86AB-CCC3C6E083FEQ24814633-755A1D31-8686-484E-8258-501C1ED82E16Q24816681-74F93438-9226-4799-8945-8FBA07F5418EQ26795463-02D4FC52-1C20-4E0A-994F-B626EF86CE48Q26824804-6F5BF73B-D029-48B5-8BE3-7D75C89D11DCQ26830063-8B60B14D-8163-4C29-888D-861387545024Q27002959-D71A7BC7-3421-4DA2-92DB-5439E4AE3CEDQ27330487-C396AE74-4F5B-444B-B4F4-BD0F9C0024B2Q28075694-F0124305-E294-4E7A-B324-0C29775D8DF2Q28111910-E8B2FF39-5A93-4E21-BB2A-79E3EA5A343BQ28345408-146F9A5D-2B9F-43BF-818D-FE73B921F752Q28469057-55563DDB-B423-4E25-8860-B5B8D8483EA9Q28469175-1C0AA8C7-D690-4F34-A3EF-E3BD364D96C2Q28469250-3255FEEF-504B-4FC9-9198-43DEAF8D6096Q28476094-EE58A583-51BD-4FCD-A392-4CE906F4FE30Q28477500-108C8796-7908-40A0-B4EF-C1D635DCBFD9Q28655602-4EBF43D0-645F-41DF-BC1F-F88F620EBFE9Q29619611-10F51077-5CFF-4DFD-A429-1AC34D2ED0D7Q30399588-35CD6AB7-A424-48F3-B977-8C080160AE01Q30425443-F44F4CDF-D9F9-4B4C-9118-C9BDAE4239FDQ33250088-5CC5F7E6-3417-4057-8FE6-E9D52E1201F9Q33265482-4125EE35-FDF8-4B72-9581-A0C9DEB7C39AQ33296883-9CFD8FBB-6084-4356-8123-460459FC24E7Q33313038-E940ECE1-685D-4326-9937-D49E4F5688FEQ33460754-266C4143-091B-43FF-BABE-53359786AF5FQ33510903-F970ACC8-1458-4BCC-8A88-9C143904CC65Q33513977-1A06351F-4BEA-40A7-811D-D2FB5E7F0210Q33517859-2D0C0037-9DD4-4D0B-94AC-138D1F36D9BAQ33521702-41C76D16-6A7C-4A6B-99E9-2F7A2EE944F8Q33724206-A6D0271A-8D8F-4F43-B46B-EF664D8CFA99Q33724247-6384607F-3DEB-4E7B-BAC0-33B1B2C43CCAQ33737646-A4A31C86-959C-4749-9A13-DAA3146B0729Q33774665-0090BAFB-5591-44E5-8C9B-3E909B304B37Q33803446-DF5FD192-F374-46FE-937F-258DE08C859FQ33804495-9C28E89A-569E-4E05-99D8-6F7AC4EA2CA5Q33805995-A3DEBD4D-BB2C-4DC7-8DCE-7C4D7CAD2D37
P2860
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Quantifying residual HIV-1 rep ...... nation antiretroviral therapy.
@en
Quantifying residual HIV-1 rep ...... nation antiretroviral therapy.
@nl
type
label
Quantifying residual HIV-1 rep ...... nation antiretroviral therapy.
@en
Quantifying residual HIV-1 rep ...... nation antiretroviral therapy.
@nl
prefLabel
Quantifying residual HIV-1 rep ...... nation antiretroviral therapy.
@en
Quantifying residual HIV-1 rep ...... nation antiretroviral therapy.
@nl
P2093
P1476
Quantifying residual HIV-1 rep ...... nation antiretroviral therapy.
@en
P2093
Markowitz M
Perelson AS
Ramratnam B
Tenner-Racz K
P304
P356
10.1056/NEJM199905273402101
P407
P577
1999-05-01T00:00:00Z